Clinical Trial Update: Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours [Phase 1]

View source ↗

Summary

The phase 1 trial of an mTOR kinase inhibitor in advanced solid tumors and lymphomas was withdrawn; no further results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma
• Solid Tumor

Drugs mentioned

• mTOR kinase inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Cancer, Advanced Solid Tumours | Phase 1 | Status: WITHDRAWN